Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9)

Details for Australian Patent Application No. 2008237940 (hide)

Owner Novartis AG

Inventors Yowe, David Langdon; Fleming, Tony; Mikhailov, Dmitri

Agent Davies Collison Cave

Pub. Number AU-A-2008237940

PCT Pub. Number WO2008/125623

Priority 60/911,654 13.04.07 US

Filing date 11 April 2008

Wipo publication date 23 October 2008

International Classifications

C07K 16/40 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against enzymes

C12N 9/64 (2006.01) Enzymes, e.g. ligases (6.) - derived from animal tissue, e.g. rennin

Event Publications

15 October 2009 PCT application entered the National Phase

  PCT publication WO2008/125623 Priority application(s): WO2008/125623

1 November 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008237944-Pyridazine-, pyridineand pyranederivatives as GPBAR1 agonisis

2008237935-Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy